Operative Therapie der Patientin mit Ovarialkarzinom

B. Schmalfeldt; Kommission Ovar der AGO

doi:10.1055/s-2007-965041

Geburtshilfe und Frauenheilkunde, Table of Contents

Geburtshilfe Frauenheilkd 2007; 67(3): R29-R52
DOI: 10.1055/s-2007-965041

GebFra-Refresher

Georg Thieme Verlag KG Stuttgart · New York

Operative Therapie der Patientin mit Ovarialkarzinom

B. Schmalfeldt¹ , Kommission Ovar der AGO

¹Frauenklinik der Technischen Universität München, München

Mitglieder der Kommission Ovar: A. du Bois, A. Burges, G. Emons, D. Fink, M. Gropp, P. Harter, A. Hasenburg, S. Hauptmann, W. Jäger, R. Kimmig, F. Kommoss, R. Kreienberg, W. Kuhn, W. Meier, K. Münstedt, O. Ortmann, J. Pfisterer, B. Richter, I. Runnebaum, B. Schmalfeldt, W. Schröder, J. Sehouli, B. Tanner, U. Wagner

Abstract

Full Text

References

Literatur

1 Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland .Krebs in Deutschland - Häufigkeiten und Trends. 4. Ausgabe. Saarbrücken; Robert-Koch-Institut 2004
2 du Bois A, Rochon J, Lamparter C, Pfisterer. AGO Organkommission Ovar . Ovarialkarzinom - Versorgungsstruktur und ‐qualität in Deutschland 2001 - 2004. Der Frauenarzt. 2005; 46 560-567
3 Schmalfeldt B, du Bois A, Burges A, Emons G, Fink D, Gropp M, Harter P, Hasenburg A, Jäger W, Kimmig R, Kiechle M, Kommoss F, Kreienberg R, Kuhn W, Lueck H J, Meier W, Münstedt K, Ortmann O, Pfisterer J, Richter B, Runnebaum I, Schmalfeldt B, Schröder W, Sehouli J, Tanner B, Wagner U, Weis J. Diagnosis and treatment of malignant ovarian tumors 2005: Recommendations of the Kommission Ovar of the AGO. Zentralbl Gynakol. 2006; 128 11-17
4 Bristow R E, Tomacruz R S, Armstrong D K, Trimble E L, Montz F J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002; 20 1248-1259
5 Griffiths C T, Parker L M, Lee S, Finkler N J. The effect of residual mass size on response to chemotherapy after surgical cytoreduction for advanced ovarian cancer: long-term-results. Int J Gynecol Cancer. 2002; 12 323-331
6 Du Bois A, Lück H J, Meier W, Adams H P, Möbus V, Costa S, Bauknecht T, Richter B, Warm M, Schröder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003; 95 1320-1329
7 Elit L, Bondy S J, Paszat L, Przybysz R, Levine M. Outcomes in surgery for ovarian cancer. Gynecol Oncol. 2002; 87 260-267
8 Earle C C, Schrag D, Neville B A, Yabroff K R, Topor M, Fahey A, Trimble E L, Bodurka D C, Bristow R E, Carney M, Warren J L. Effect of surgeon speciality on process of care and outcomes for ovarian cancer patients. J Natl Cancer Inst. 2006; 98 151-154
9 Engelen M JA, Kos H E, Willemse P HB. et al . Surgery by consultant oncologist improves survival in patients with ovarian carcinoma. Cancer. 2006; 106 589-598
10 Lecuru F, Desfeux P, Camatte S, Bissery A, Robin F, Blanc B, Querleu D. Stage I ovarian cancer: comparison of laparoscopy and laparotomy on staging and survival. Eur J Gynaecol Oncol. 2004; 25 571-576
11 Vergote I, De Brabanter J, Fyles A, Bertelsen K, Einhorn N, Sevelda P, Gore M E, Kaern J, Verrelst H, Sjovall K, Timmerman D, Vandewalle J, Van Gramberen M, Trope C G. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet. 2001; 357 176-182
12 Negishi H, Takeda M, Fujimoto T, Todo Y, Ebina Y, Watari H, Yamamoto R, Minakami H, Sakuragi N. Lymphatic mapping and sentinel node identification as related to the primary sites of lymph node metastasis in early stage ovarian cancer. Gynecol Oncol. 2004; 94 161-166
13 Trimbos J B, Vergote I, Bolis G, Vermorken J B, Mangioni C, Madronal C. et al . Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer - Adjuvant Chemotherapy in Ovarian Neoplasm Trial. J Natl Cancer Inst. 2003; 95 113-125
14 Zanetta G, Chiari S, Rota S, Bratina G, Maneo A, Torri V, Mangioni C. Conservative surgery for stage I ovarian carcinoma in women of childbearing age. Br J Obstet Gynaecol. 1997; 104 1030-1035
15 Eisenkop S M, Spirtos N M. Procedures required to accomplish complete cytoreductin of ovarian cancer. Is there a correlation with “biological aggressiveness” and survival?. Gynecol Oncol. 2001; 82 435-441
16 Aletti G D, Dowdy S C, Podratz K C, Cliby W A. Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecol Oncol. 2006; 100 283-287
17 Kuhn W, Florack G, Roder J, Schmalfeldt B, Rust M, Ulm K, Späthe K, Jänicke F, Siewert J R, Graeff H. The influence of upper abdominal surgery on perioperative morbidity and mortality in patients with advanced ovarian cancer FIGO III and FIGO IV. Int J Gynecol Cancer. 1998; 8 56-63
18 Benedetti-Panici P B, Maggioni A, Hacker N, Landoni F, Ackermann S, Campagnutta E, Tamussino K, Winter R, Pellegrino A, Greggi S, Angioli R, Manci N, Scambia G, Dell'Anna T, Fossati R, Floriani I, Rossi R S, Grassi R, Favalli G, Raspagliesi F, Giannarelli D, Martella L, Mangioni C. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst. 2005; 97 560-566
19 Crawford S C, Vasey P A, Paul J, Hay A, Davis J A, Kaye S B. Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC‐1 trial. J Clin Oncol. 2005; 23 8802-8811
20 Bristow R E, Montz F J, Lagasse L D, Leuchter R S, Karlan B Y. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol. 1999; 72 278-287
21 Tentes A-AK, Mirelis C G, Markakidis S K, Bekiaridou I G, Bougioukas I G, Xanthoulis A I, Tsalkidou E G, Zafiropoulos G H, Nikas L H. Long-term survival in advanced ovarian carcinoma following cytoreductive surgery with standard peritonectomy procedures. Int J Gynecol Cancer. 2006; 16 490-495
22 Van der Burg M E, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, Lacave A J, Nardi M, Renard J, Pecorelli S. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med. 1995; 332 629-634
23 Rose P G, Nerenstone S, Brady M F, Clarke-Pearson D, Olt G, Rubin S C, Moore D H, Small J M. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med. 2004; 351 2489-2497
24 Arbeitsgemeinschaft Gynäkologische Endoskopie (AGE) . Leitlinie zur laparoskopischen Operation von Ovarialtumoren. Frauenarzt. 1998; 39 1055-1056
25 Colombo N, Parma G, Lapresa M T, Maggi F, Piantanda P, Maggioni A. Role of conservative surgery in ovarian cancer: the European experience. Int J Gynecol Cancer. 2005; 15 206-211

Prof. Dr. Barbara Schmalfeldt Sprecherin der Kommission Ovar der AGO

Frauenklinik der Technischen Universität München

Ismaninger Straße 22

81675 München

Email: barbara.schmalfeldt@lrz.tum.de